洛吡莫德(Losmapimod) - 药物靶点：DUX4 x MAPK11 x p38α_在研适应症：面肩肱型肌营养不良，1a型面肩肱型肌营养不良症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Losmapimod (USAN/INN)、FTX-1821、GS-856553

+ [8]

靶点

DUX4 x MAPK11 x p38α

作用机制

DUX4基因调节剂(Double homeobox protein 4 gene modulators)、MAPK11抑制剂(mitogen-activated protein kinase 11 inhibitors)、p38α抑制剂(P38 α 丝裂原活化蛋白激酶抑制剂)

治疗领域

神经系统疾病遗传病与畸形皮肤和肌肉骨骼疾病+ [1]

在研适应症

面肩肱型肌营养不良1a型面肩肱型肌营养不良症

非在研适应症

急性冠状动脉综合征动脉粥样硬化新型冠状病毒感染+ [12]

原研机构

GSK Plc

在研机构

Fulcrum Therapeutics, Inc.

非在研机构

GSK Plc

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)

结构

分子式C22H26FN3O2

InChIKeyKKYABQBFGDZVNQ-UHFFFAOYSA-N

CAS号585543-15-3

关联

65

项与洛吡莫德相关的临床试验

EUCTR2022-000389-16-ES / Unknown status临床3期

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients with Facioscapulohumeral Muscular Dystrophy

开始日期2022-07-14

申办/合作机构

Fulcrum Therapeutics, Inc.

NCT05397470 / Active, not recruiting临床3期

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

This is a study to evaluate the safety and efficacy of losmapimod in treating participants with Facioscapulohumeral Muscular Dystrophy (FSHD). Participants diagnosed with Facioscapulohumeral muscular dystrophy type 1 (FSHD1) or Facioscapulohumeral muscular dystrophy type 2 (FSHD2) will participate in Part A (Placebo-controlled treatment period) and will be randomized in a 1:1 ratio to receive losmapimod 15 milligrams (mg) or placebo orally twice daily (BID). Upon completion of Part A, participants will have the option to rollover into Part B (open-label extension) to evaluate the long-term safety, tolerability, and efficacy of losmapimod and will receive losmapimod 15 mg orally BID.

开始日期2022-06-16

申办/合作机构

Fulcrum Therapeutics, Inc.

NCT05002231 / Completed临床1期

A Phase 1, Open-Label, 3-Period, Randomized, Single-Dose, Crossover Study to Assess the Relative Bioavailability and the Effect of Food on the Pharmacokinetics of a New 15 mg Tablet of Losmapimod Versus the Current 7.5 mg Tablet

This is a study to assess the relative bioavailability and the effect of food on the pharmacokinetics of a new 15 mg tablet formulation of losmapimod

开始日期2021-08-19

申办/合作机构

Fulcrum Therapeutics, Inc.

100 项与洛吡莫德相关的临床结果

登录后查看更多信息

100 项与洛吡莫德相关的转化医学

登录后查看更多信息

100 项与洛吡莫德相关的专利（医药）

登录后查看更多信息

57

项与洛吡莫德相关的文献（医药）

2023-09-30·Biomedicines

Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells.

Article

作者: Carestia, Agostina ; Wasiak, Sylwia ; Fu, Li ; Gilham, Dean ; Tsujikawa, Laura M ; Sarsons, Christopher D ; Rakai, Brooke D ; Stotz, Stephanie C ; Kulikowski, Ewelina ; Sweeney, Michael

Facioscapulohumeral dystrophy (FSHD) is a muscle disease caused by inappropriate expression of the double homeobox 4 (DUX4) gene in skeletal muscle, and its downstream activation of pro-apoptotic transcriptional programs. Inhibitors of DUX4 expression have the potential to treat FSHD. Apabetalone is a clinical-stage bromodomain and extra-terminal (BET) inhibitor, selective for the second bromodomain on BET proteins. Using primary human skeletal muscle cells from FSHD type 1 patients, we evaluated apabetalone for its ability to counter DUX4's deleterious effects and compared it with the pan-BET inhibitor JQ1, and the p38 MAPK inhibitor-and DUX4 transcriptional repressor-losmapimod. We applied RNA-sequencing and bioinformatic analysis to detect treatment-associated impacts on the transcriptome of these cells. Apabetalone inhibited the expression of DUX4 downstream markers, reversing hallmarks of FSHD gene expression in differentiated muscle cells. JQ1, but not apabetalone, was found to induce apoptosis. While both BET inhibitors modestly impacted differentiation marker expression, they did not affect myotube fusion. Losmapimod also reduced expression of DUX4 target genes but differed in its impact on FSHD-associated pathways. These findings demonstrate that apabetalone inhibits DUX4 target gene expression and reverses transcriptional programs that contribute to FSHD pathology, making this drug a promising candidate therapeutic for FSHD.

2023-08-04·Journal of proteome research

Comparison of Quantitative Mass Spectrometric Methods for Drug Target Identification by Thermal Proteome Profiling.

Article

作者: Martin, Mathew P ; Dueñas, Maria Emilia ; Trost, Matthias ; George, Amy L ; Sidgwick, Frances R ; Marín-Rubio, José Luis ; Watt, Jessica E

Thermal proteome profiling (TPP) provides a powerful approach to studying proteome-wide interactions of small therapeutic molecules and their target and off-target proteins, complementing phenotypic-based drug screens. Detecting differences in thermal stability due to target engagement requires high quantitative accuracy and consistent detection. Isobaric tandem mass tags (TMTs) are used to multiplex samples and increase quantification precision in TPP analysis by data-dependent acquisition (DDA). However, advances in data-independent acquisition (DIA) can provide higher sensitivity and protein coverage with reduced costs and sample preparation steps. Herein, we explored the performance of different DIA-based label-free quantification approaches compared to TMT-DDA for thermal shift quantitation. Acute myeloid leukemia cells were treated with losmapimod, a known inhibitor of MAPK14 (p38α). Label-free DIA approaches, and particularly the library-free mode in DIA-NN, were comparable of TMT-DDA in their ability to detect target engagement of losmapimod with MAPK14 and one of its downstream targets, MAPKAPK3. Using DIA for thermal shift quantitation is a cost-effective alternative to labeled quantitation in the TPP pipeline.

2023-06-03·Cureus

Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD): A Systematic Review

Review

作者: Astudillo Moncayo, Olga M ; Andrade, Andres F ; Oña, Sebastian ; Gallegos, Camila ; Buj, Maja J ; Mosquera, Johanna ; Ortiz, Juan Fernando ; Aguirre, Alex S ; Muyolema Arce, Veronica E

Facioscapulohumeral muscular dystrophy (FSHD) is the third most common type of muscular dystrophy. This disease presents as a slowly progressive asymmetric muscle weakness that involves the facial, scapular, and upper arm muscles mainly. Currently, there is no established consensus on this disease treatment in terms of medications. We assessed the response to the treatment of the drugs utilized in clinical trials by performing a systematic literature review in English using the preferred reporting items for systematic reviews (PRISMA) and meta-analyses. We only used human clinical trials in patients diagnosed with FSHD that received consistent pharmacological treatment. We included 11 clinical trials that fulfilled our criteria. We concluded that albuterol had statistically significant results in three out of four clinical trials, with improved elbow flexors muscle strength. Vitamin C, vitamin E, zinc gluconate, and selenomethionine showed significant improvement in the maximal voluntary contraction and endurance limit time of quadriceps muscle. At the same time, diltiazem and MYO-029 demonstrate no improvement in function, strength, or muscle mass. Losmapimod, currently in phase I of the ReDUX4 trial, showed promising results. Peradventure, more clinical trials are still needed to address this subject. Nevertheless, this review provides a clear and concise update on the treatment for this disease.

128

项与洛吡莫德相关的新闻（医药）

2024-06-12

·GlobeNewswire-Health Care

Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress

CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced upcoming presentations to be made at the 31st Annual FSHD Society International Research Congress being held June 13-14, 2024 in Denver, Colorado, including an abstract outlining the baseline characteristics of patients enrolled in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD). The presentations to be made are as follows: Title: Characteristics of the Enrolled Population in the Phase 3 REACH Trial in Facioscapulohumeral Muscular Dystrophy (FSHD) Poster Number: P7.01Format: Poster First Author: Nicol Voermans, MD, PhD, Radboud University Medical CenterPresentation Date and Time: Thursday, June 13, 2024, between 5:30-8:30 PM MDT Title: Facioscapulohumeral Muscular Dystrophy (FSHD) Disease Progression and Losmapimod Efficacy Assessed by Reachable Workspace in Both ArmsPresentation Number: S6.06Format: Oral presentationPresenter: Joost Kools, MD, Radboud University Medical CenterPresentation Date and Time: Friday, June 14, 2024 at 3:50 PM MDT Title: Safety and Tolerability of Losmapimod for the Treatment of FSHDPoster Number: P6.05Format: Poster First Author: Mihaela Levitchi Benea, MD, Executive Director of Medical Affairs at Fulcrum TherapeuticsPresentation Date and Time: Thursday, June 13, 2024, between 5:30-8:30 PM MDT Title: Reliability and Validity of Reachable Workspace Total Score with Wrist Weights in Facioscapulohumeral Muscular DystrophyPoster Number: P7.06Format: Poster First Author: Lena Hubig, Acaster Lloyd ConsultingPresentation Date and Time: Thursday, June 13, 2024, between 5:30-8:30 PM MDT The presentation and posters will be available on the publications page of Fulcrum’s website at https://www.fulcrumtx.com. About Fulcrum TherapeuticsFulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD) and other hemoglobinopathies. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn. Contact:Chris CalabreseLifeSci Advisors, LLCccalabrese@lifesciadvisors.com917-680-5608

临床3期

2024-05-17

·CPHI制药在线

频繁出手，赛诺菲努力打造罕见病帝国

关注并星标CPHI制药在线近日，赛诺菲动作频频，先是与生物制药公司Fulcrum Therapeutics（简称Fulcrum）达成合作，获得其在研新药Losmapimod在美国以外所有地区的独家开发和商业化权益；两天后，又宣布将加大对在法国的三个生产基地的投资，总额超10亿欧元。一系列动作背后，折射出了赛诺菲面对王牌产品即将迎来专利悬崖的焦虑和打造罕见病帝国的决心。潜在超10亿美元付款，引进一款罕见病产品近日，赛诺菲发布了2024年第一季度财报，公司销售收入为104.64亿欧元（约112.24亿美元），同比强劲增长6.7%。在制药部门，其核心大单品靶向IL-4R单抗药物——度普利尤单抗（Dupixent，商品名：达必妥）一季度销售额为28.35亿欧元，贡献了制药部门绝大部分业绩。然而Dupixent专利将于2027年到期，为了应对专利悬崖，赛诺菲开始不断向外拓展合作。5月13日，赛诺菲与Fulcrum达成独家合作协议，赛诺菲将获得Fulcrum的Losmapimod（洛吡莫德）的开发和商业化权益。Fulcrum将获得8000万美元首付款，以及潜在高达9.75亿美元的监管和销售里程碑付款。Losmapimod是一款选择性p38α/β丝裂原活化蛋白激酶（MAPK）抑制剂，旨在通过阻断p38α和p38β蛋白来降低双同源盒转录因子4（DUX4）基因的活性。Losmapimod最初由GSK研发，2019年，Fulcrum从GSK手中收购了Losmapimod的所有权益。目前，Losmapimod主要被用来开发治疗面肩肱型肌营养不良症（FSHD）。FSHD是一种罕见且严重的肌肉萎缩症，其特征是骨骼肌脂肪浸润导致肌肉萎缩，主要累及面部、肩胛骨等，逐渐导致患者日常活动能力下降、独立性丧失等，目前尚无批准的治疗方法。在FSHD中，约95%的患者是由于4 号染色体变异，造成DUX4基因异常表达所引起。因此，Losmapimod在FSHD领域具有很大的潜力。在治疗FSHD的IIb期临床试验中，评估了Losmapimod治疗FSHD的安全性和有效性。试验共招募80名患有1型 FSHD且DUX4表达抑制丧失的患者。结果显示，与安慰剂组相比，Losmapimod组FSHD患者的DUX4驱动的基因表达水平呈现出下降趋势但并无统计学意义。但是Losmapimod组患者的肌肉脂肪浸润情况、肌肉萎缩情况和生活质量均有所改善。因此，Fulcrum还是决定将Losmapimod推进至III期阶段。22亿美元，收购AATD领域在研治疗药物除了收购Fulcrum外，今年1月，赛诺菲和Inhibrx达成合作协议，将收购与INBRX-101相关的所有资产和负债，该笔交易总价值为22亿美元。INBRX-101是一款拟用于治疗 α-1抗胰蛋白酶缺乏症（AATD）的重组人AAT-Fc融合蛋白候选治疗物，目前正在注册试验中。AATD是一种遗传性孤儿病，其特征是A1AT蛋白水平不足，这会导致患者的肺组织及其功能丧失，进而导致患者的预期寿命缩短。INBRX-101有望使AATD患者在减少用药次数（每月一次）的情况下实现血清α-1抗胰蛋白酶水平的正常化。目前正在开展 II 期临床试验，以进一步评估治疗AATD患者的潜力。以临床价值为导向，赛诺菲旨在打造罕见病帝国赛诺菲在罕见病领域的布局可以追溯到2011年。当年，赛诺菲以201亿美元收购Genzyme（健赞），入局罕见病领域。此后，赛诺菲不断通过并购丰富罕见病管线，包括通过收购Ablynx和Bioverativ，分别从两家公司获得了纳米抗体新药Cablivi和Eloctate、Alprolix等多款血友病新药等。目前，赛诺菲在罕见病领域共布局了11条在研管线，其中6个候选产品处于III期临床。2023年，罕见病领域产品成为公司业绩主要来源之一，其中Nexviazyme（庞贝病）、Enjaymo（冷凝集素病）、Xenpozyme（酸性鞘磷脂酶缺乏症）3款罕见病产品表现亮眼。为了满足新药产能需求，赛诺菲近日表示，将在法国的三个生产基地Vitry、Le Trait、Lyon Gerland投资超10亿欧元，以增加新药和疫苗产能。其中赛诺菲将10 亿欧元投向Vitry工厂，以将其单克隆抗体产能提高一倍，包括治疗慢性阻塞性肺病（COPD）、多发性硬化症等疾病的药物。近几年，赛诺菲正在进行重组优化，如剥离免疫肿瘤产品开发公司Amunix Pharmaceuticals、关闭NK细胞疗法开发公司Kiadis Pharma、削减与IGM Biosciences的合作，放弃原计划在肿瘤学领域的三个靶点等，以筹集资金，来加速布局罕见病等领域。随着候选药物研究的快速推进与产能不断扩张，赛诺菲距离打造罕见病帝国的梦想，正在越来越近。参考来源：1. Press release: Sanofi to acquire Inhibrx, adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline.2. Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Sub.3. strate Reduction Therapy for the Treatment of Pompe Disease；MazeFDA Approves First Treatment for Acid Sphingomyelinase Deficiency, a Rare Genetic Disease. Retrieved August 31, 2022 from https://www.sanofi.com/en/media-room/press-releases/2022/2022-06-28-05-30-00-2469974.【智药研习社近期线下课程预告】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

引进/卖出并购临床3期财报

2024-05-15

·精准药物

10.55亿美元！赛诺菲获3期p38α/β MAPK抑制剂的独家授权

2024年5月13日，Fulcrum Therapeutics（简称“Fulcrum”）宣布，公司已与赛诺菲（Sanofi）就losmapimod达成合作，赛诺菲将获得在美国境外独家商业化losmapimod的权利。根据协议条款，Fulcrum 将获得 8000 万美元的预付款，并有资格基于监管和销售的里程碑中额外获得高达 9.75 亿美元的潜在付款，以及分级递增特许权使用费。Losmapimod是一款口服小分子抑制剂，正在开发用于治疗面肩肱型肌营养不良症（FSHD），目前处于III期临床阶段。公司预计将于2024年第四季度公布其全球3 期REACH临床试验主要数据，并计划在美国、欧洲、日本和其他地区递交上市申请。关于LosmapimodLosmapimod是一款选择性p38α/β 丝裂原激活蛋白激酶 (MAPK) 抑制剂，旨在通过阻断p38α和p38β蛋白来降低DUX4基因的活性；在FSHD中，有约95%的患者是由于4 号染色体变异，造成DUX4 基因异常表达所引起。Losmapimod最早由葛兰素史克（“GSK”）开发，2019年4月，Fulcrum从GSK手中收购了losmapimod的所有权益。目前，该药物已获得FDA快速通道认定和治疗FSHD的孤儿药认定，正在一项针对 FSHD 患者的 3 期多中心随机、双盲、安慰剂对照、为期 48 周的平行组研究中进行评估。2期ReDUX4 试验旨在评估losmapimod治疗FSHD的安全性和有效性。试验纳入了18-65岁患有1型FSHD且通过基因分型确定的DUX4表达抑制丧失的成年人，这些患者Ricci临床严重程度评分为2-4，并且使用MRI判断至少有一块骨骼肌适合活检。受试者被随机分配(1:1)口服losmapimod(15mg，每天两次)或相似的安慰剂，为期48周。主要终点是通过定量RT-PCR判定的骨骼肌活检样本中DUX4驱动的基因表达从起始到第16周或第36周的变化；次要终点为安全性和耐受性评估。结果显示，虽然肌肉活检中DUX4驱动的基因表达变化的主要终点在治疗组和安慰剂组之间没有显示出显著差异，但losmapimod与结构和功能结果的改善相关，包括肌肉脂肪浸润和可及工作区（衡量肩带功能的指标）以及患者报告的与安慰剂相比的总体变化印象。此外，losmapimod具有良好的耐受性，没有报告与该药物相关的严重不良事件，也没有因不良事件而中断治疗。关于FSHDFSHD 是一种遗传性、渐进性萎缩疾病，常见于面部、肩胛和上臂肌肉，是第二常见的肌肉萎缩疾病，至今仍无获批疗法。FSHD 患者通常在20 岁前出现眼、嘴、肩膀、上臂和小腿肌无力及萎缩；随着病情加重，FSHD 可能会扩散至腹部和臀部肌肉，有约20%的患者在50 岁以前会需要使用轮椅行走。FSHD 发展速度通常较为缓慢，且不具有致命性，但可能会严重影响患者的生活质量，他们有些甚至需要借助呼吸器才能正常生活。美国面肩肱协会（FSH Society）估计全球有约87 万人患有该疾病。关于赛诺菲在FSHD的布局2022年 10 月，赛诺菲曾与生物技术公司 miRecule达成合作和独家许可协议，以开发和商业化新型抗体-RNA 偶联药物（ARC）用于治疗FSHD。根据合作协议条款，赛诺菲将获得新型FSHD疗法的全球独家许可，而 miRecule 将先收到一笔约 3000 万美元的预付款，未来将会收到总额接近 4 亿美元的里程碑付款以及分级特许权使用费。miRecule 专有的、基于基因组的DREAmiR发现平台，能够识别关键RNA 靶标，用以作为特定族群病患药物的开发。miRecule 所开发的专有RNA 疗法具有改善的药理学特性，可与抗体偶联以递送至靶标组织。例如，公司先导项目MC-30 可取代在头颈癌中具肿瘤抑制活性的微RNA-30（miRNA-30），有约一半的头颈癌患者失去miRNA-30 的表达；另一个项目是RNA 疗法MC-DX4，可消除FSHD患者体内DUX4 基因的表达。参考资料1、Tawil R, Wagner K R, Hamel J I, et al. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial[J]. The Lancet Neurology, 2024, 23(5): 477-486.2、各公司官网3、香港济民药业、东北证券、猎药人俱乐部声明：发表/转载本文仅仅是出于传播信息的需要，并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断，后果自负。若有侵权，告知必删！长按关注本公众号粉丝群/投稿/授权/广告等请联系公众号助手觉得本文好看，请点这里↓

临床3期孤儿药临床结果并购临床成功

100 项与洛吡莫德相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09639	洛吡莫德	-	DB12270

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
面肩肱型肌营养不良	临床3期	美国	Fulcrum Therapeutics, Inc.	2022-06-16
面肩肱型肌营养不良	临床3期	加拿大	Fulcrum Therapeutics, Inc.	2022-06-16
面肩肱型肌营养不良	临床3期	丹麦	Fulcrum Therapeutics, Inc.	2022-06-16
面肩肱型肌营养不良	临床3期	法国	Fulcrum Therapeutics, Inc.	2022-06-16
面肩肱型肌营养不良	临床3期	德国	Fulcrum Therapeutics, Inc.	2022-06-16
面肩肱型肌营养不良	临床3期	意大利	Fulcrum Therapeutics, Inc.	2022-06-16
面肩肱型肌营养不良	临床3期	荷兰	Fulcrum Therapeutics, Inc.	2022-06-16
面肩肱型肌营养不良	临床3期	西班牙	Fulcrum Therapeutics, Inc.	2022-06-16
面肩肱型肌营养不良	临床3期	英国	Fulcrum Therapeutics, Inc.	2022-06-16
新型冠状病毒感染	临床3期	美国	Fulcrum Therapeutics, Inc.	2020-08-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04511819 (LOSVID, CTgov)	临床3期	新型冠状病毒感染	52	Placebo oral tablet	範廠夢選製網醖鏇膚鹹(繭積遞夢膚構繭積糧製) = 窪衊憲衊獵鑰範範餘齋鹽壓餘選襯淵廠積鹹積 (鬱鬱簾醖觸鏇蓋築糧餘, 衊憲壓觸築鹽顧壓餘鹹 ~ 齋簾鹹窪觸繭壓艱獵窪) 更多	-	2024-03-13
AAN2023	临床2期	面肩肱型肌营养不良	-	Losmapimod 15 mg	鑰鑰廠鏇憲築膚衊遞憲(鹹衊選觸窪餘襯窪糧齋) = 壓鬱範壓壓顧齋廠衊遞鏇窪憲壓齋鏇齋鹽蓋廠 (簾願醖遞簾築願壓鏇獵 ) 更多	积极	2023-04-25
				Placebo	鑰鑰廠鏇憲築膚衊遞憲(鹹衊選觸窪餘襯窪糧齋) = 簾鏇鹽顧繭淵鹽醖遞願鏇窪憲壓齋鏇齋鹽蓋廠 (簾願醖遞簾築願壓鏇獵 ) 更多
NCT04264442 (ReDUX4, MDA2023) 人工标引	临床2期	面肩肱型肌营养不良	74	Losmapimod 15 mg (LOS/LOS)	夢觸遞襯糧窪糧齋艱鏇(夢衊鹹醖網積鏇餘觸願) = Fall (22.4%), headache (14.5%), arthralgia (7.9%), and back pain (7.9%) 膚鏇窪鏇構繭夢糧壓醖 (窪鏇鬱膚鑰積築鑰夢壓 ) 更多	积极	2023-03-19
				Placebo+Losmapimod 15 mg (PBO/LOS)
ReDUX4 (MDA2022)	临床2期	面肩肱型肌营养不良	80	Losmapimod 15 mg	顧獵繭衊鏇廠鏇鑰鬱積(鹹廠壓鏇簾鹹憲構顧鹽) = the losmapimod arm had either improvements or no worsening, particularly in Q1 and Q3 (above shoulder), and Q5 (posterior inferior) 觸襯製範艱艱鹽餘築蓋 (夢淵齋範窪觸鹹醖範積 )	-	2022-03-13
				Placebo
ReDUX4 (MDA2022)	临床2期	面肩肱型肌营养不良	-	Losmapimod 15 mg	選淵觸願壓醖夢遞壓襯(壓糧積簾鑰製壓顧選鹹) = 鑰衊網繭膚簾蓋糧積醖衊餘蓋網膚顧艱淵壓獵 (窪鏇製網選鏇醖獵窪餘 ) 更多	-	2022-03-13
				Placebo	選淵觸願壓醖夢遞壓襯(壓糧積簾鑰製壓顧選鹹) = 鏇鑰築簾艱鹹獵構鹽鬱衊餘蓋網膚顧艱淵壓獵 (窪鏇製網選鏇醖獵窪餘 ) 更多
NL68539.056.18 (Pubmed \| Br J Clin Pharmacol)	临床1期	面肩肱型肌营养不良	-	Losmapimod 7.5 mg	獵壓餘艱鬱鑰鏇簾願簾(糧齋憲壓遞蓋獵鏇鹽襯) = were mild and self-limited 齋觸積衊艱製壓積醖網 (網範顧窪選艱鏇窪鏇鑰 )	-	2021-04-30
				Losmapimod 15 mg
NCT04003974 (ReDUX4, Corporate Publications) 人工标引	临床2期	面肩肱型肌营养不良 DUX4-driven gene Expression	29	Losmapimod	願鏇構襯壓築獵鏇觸糧(膚願餘獵醖夢獵鏇鏇糧) = Losmapimod arm:-38 fold（in 3 muscle biopsies pts）；+3.7 fold（in all 15 pts); Placebo:-5.4 fold（in 5 muscle biopsies pts）；+2.8 fold（in all 14 pts）鑰廠鬱積選壓簾鹽鹹膚 (鹹艱蓋繭構憲餘窪膚鏇 )	积极	2020-08-11
				Placebo
1557 (AAN2020)	临床1期	面肩肱型肌营养不良 DUX4	-	Losmapimod 7.5 mg	顧獵遞蓋製襯襯醖齋窪(夢淵簾觸醖鹽範窪鬱蓋) = 襯醖膚遞選蓋艱窪淵鑰醖鬱襯壓齋觸膚夢餘襯 (醖鹹鑰構夢製鹹網選襯 )	积极	2020-04-14
				Losmapimod 15 mg	顧獵遞蓋製襯襯醖齋窪(夢淵簾觸醖鹽範窪鬱蓋) = 鬱壓構鏇顧遞鹽醖糧鏇醖鬱襯壓齋觸膚夢餘襯 (醖鹹鑰構夢製鹹網選襯 )
NCT00633022 (A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging, CTgov)	临床2期	动脉粥样硬化	99	LOSMAPIMOD 7.5 MG (Losmapimod 7.5 mg Twice Daily)	獵淵繭壓鏇繭襯選醖製(築鏇鹽觸選繭遞鏇製艱) = 遞鑰鹽淵網鏇願網範鑰構鹹艱夢築獵膚艱餘齋 (糧範糧鹹積膚蓋選淵餘, 醖觸繭壓觸廠艱襯繭顧 ~ 齋積夢夢憲鏇襯鹹淵壓) 更多	-	2018-10-17
				LOSMAPIMOD 7.5 MG (Losmapimod 7.5 mg Once Daily)	獵淵繭壓鏇繭襯選醖製(築鏇鹽觸選繭遞鏇製艱) = 醖遞艱廠壓窪範憲膚鑰構鹹艱夢築獵膚艱餘齋 (糧範糧鹹積膚蓋選淵餘, 膚壓齋壓簾網蓋膚鹹築 ~ 鏇窪遞膚築選壓網積窪) 更多
NCT02299375 (CTgov)	临床2期	慢性阻塞性肺疾病	184	Placebo tablets+Salbutamol MDI (Placebo)	襯膚窪餘鹽壓鹽選簾顧(遞夢鹹觸獵積築艱積餘) = 鹽艱憲齋鏇壓顧遞積顧衊構範艱齋築構齋鹽顧 (築範淵觸網齋製顧積選, 窪艱窪網選觸襯構夢膚 ~ 壓積蓋壓糧壓壓製膚積) 更多	-	2018-07-13
				Losmapimod tablets+Salbutamol MDI (Losmapimod 15 mg)	襯膚窪餘鹽壓鹽選簾顧(遞夢鹹觸獵積築艱積餘) = 網糧鹽積願鬱廠製鹽觸衊構範艱齋築構齋鹽顧 (築範淵觸網齋製顧積選, 積艱遞壓願醖鏇鏇築襯 ~ 衊廠鹹顧餘積簾醖鹹餘) 更多